Real‐world impact of once‐weekly subcutaneous semaglutide after 2 years of follow‐up: Results from a nationwide observational study in people with type 2 diabetes.

Aim: To investigate the impact of treatment with once‐weekly subcutaneous semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), for up to 2 years in people with type 2 diabetes (T2D) managed in routine clinical practice. Materials and methods: The study was based on data from national registries. People who redeemed at least one prescription of semaglutide and had 2 years of follow‐up were included. Data were collected at baseline and after 180, 360, 540 and 720 days of treatment (all timepoints ± 90 days). Results: In total, 9284 people redeemed at least one semaglutide prescription (intention‐to‐treat) and 4132 people redeemed semaglutide continuously (on‐treatment). For the on‐treatment cohort, the median (interquartile range) age was 62.0 (16.0) years, diabetes duration was 10.8 (8.7) years, and glycated haemoglobin (HbA1c) level was 62.0 (18.0) mmol/mol at baseline. A subset of the on‐treatment cohort, comprising 2676 people, had HbA1c measurements at baseline and at least once during 720 days. The mean (95% confidence interval) changes in HbA1c after 720 days were –12.6 (–13.6; –11.6) mmol/mol (P < 0.001) for GLP‐1RA‐naïve people, and –5.6 (–6.2; –5.0) mmol/mol (P < 0.001) for GLP‐1RA‐experienced people. Similarly, 55% of GLP‐1RA‐naïve people and 43% of GLP‐1RA‐experienced people reached a HbA1c target of ≤53 mmol/mol after 2 years. Conclusions: People treated with semaglutide in routine clinical practice experienced clinically relevant and sustained improvements in glycaemic control after 180, 360, 540 and 720 days, irrespective of former GLP‐1RA exposure, effects which were comparable with those observed in clinical studies. These results support the use of semaglutide in routine clinical practice for the long‐term management of T2D. [ABSTRACT FROM AUTHOR]